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Background: High platelet reactivity with suboptimal platelet inhibition during clopidogrel therapy is an independent predictor of ischemic 
events in coronary stented patients. We evaluated whether supplemental St. John’s wort (SJW), a cytochrome P450 (CYP)3A4 and CYP2C19 inducer, 
enhances the pharmacodynamic efficacy of clopidogrel in clopidogrel hypo-responsive volunteers and stented patients.
Methods: Two studies were conducted: 1) a prospective , open-labeled, control study in 10 volunteers, and 2) a randomized, placebo controlled, 
double blind study in 14 post-coronary stent patients who had a suboptimal antiplatelet response to clopidogrel. Healthy volunteers, after baseline 
testing and a 7-day washout period, received SJW 300mg TID for 14 days. Platelet aggregation was measured at baseline before and at 2, 4, and 6 
hours after a clopidogrel 300mg load and at day-21 (without maintenance therapy) after SJW therapy. The hepatic CYP3A4 metabolic activity was 
measured by the erythromycin breath test (0 and 4) hours at baseline and day-21. After demonstration of hypo-responsiveness, patients receiving 
chronic clopidogrel 75mg daily maintenance therapy were randomized to receive SJW or placebo in a 1:1 ratio. Platelet aggregation was measured 
before and after 14 days of SJW or placebo.
Results: In volunteers, SJW treatment decreased platelet aggregation after a 300mg clopidogrel load from 59±14% at baseline to 40±15% at 2 
hours, p = 0.02; from 56±10% to 44±13% at 4 hours, p<0.03; and from 55±14% to 37±14% at 6 hours, p=0.01; and increased hepatic CYP3A4 
metabolic activity from 2 ± 0.4% at baseline to 3 ± 0.6% 14CO2 exhaled/hour after 14 days, p = 0.002. In patients, SJW therapy decreased 
platelet reactivity measured by platelet receptor P2Y12 reaction units (222±36 at baseline vs. 166±57 at 14-days, p=0.01), and decreased platelet 
aggregation (65±13% vs. 41±15%, p=0.0006).
Conclusion: St. John’s wort enhances the antiplatelet effect of clopidogrel in hypo-responsive volunteers and patients by induction of the hepatic 
CYP3A4 isoenzyme. Future studies examining the effect of SJW to enhance the potency of clopidogrel are warranted.
